Literature DB >> 12369590

Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.

.   

Abstract

This final rule is issued by the Deputy Administrator of the Drug Enforcement Administration (DEA) to reschedule buprenorphine from a Schedule V narcotic to a Schedule III narcotic under the Controlled Substances Act (CSA). This action is based on a rescheduling recommendation by the Department of Health and Human Services (DHHS) and a DEA review indicating that buprenorphine meets the criteria of a Schedule III narcotic. The DEA published a proposed rule to reschedule buprenorphine on March 21, 2002 (67 FR 13114). The comment period was extended for an additional 30 days until May 22, 2002 (67 FR 20072). The DEA received ten comments but no requests for hearings. This final action will impose the regulatory controls and criminal sanctions of a Schedule III narcotic on those persons who handle buprenorphine or products containing buprenorphine

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12369590

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  6 in total

1.  Leveraging black-market street buprenorphine pricing to increase capacity to treat opioid addiction, 2010-2018.

Authors:  Yulin Hswen; Amanda Zhang; John S Brownstein
Journal:  Prev Med       Date:  2020-04-27       Impact factor: 4.018

Review 2.  The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Authors:  Matthew W Johnson; Roland R Griffiths; Peter S Hendricks; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

3.  Crowdsourcing black market prices for prescription opioids.

Authors:  Nabarun Dasgupta; Clark Freifeld; John S Brownstein; Christopher Mark Menone; Hilary L Surratt; Luke Poppish; Jody L Green; Eric J Lavonas; Richard C Dart
Journal:  J Med Internet Res       Date:  2013-08-16       Impact factor: 5.428

4.  The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial.

Authors:  Jamshid Ahmadi; Mina Sefidfard Jahromi; Zahra Ehsaei
Journal:  Trials       Date:  2018-08-29       Impact factor: 2.279

Review 5.  Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion.

Authors:  Lynn Webster; Jeffrey Gudin; Robert B Raffa; Jay Kuchera; Richard Rauck; Jeffrey Fudin; Jeremy Adler; Theresa Mallick-Searle
Journal:  Pain Med       Date:  2020-04-01       Impact factor: 3.750

Review 6.  Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain.

Authors:  Joseph V Pergolizzi; Robert B Raffa
Journal:  J Pain Res       Date:  2019-12-13       Impact factor: 3.133

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.